BIO-CANDESARTAN TABLET
Land: Kanada
Tungumál: enska
Heimild: Health Canada
Vara einkenni
(SPC)
16-06-2016
Sum skjöl fyrir þessa vöru eru ekki tiltæk eins og er, þú getur sent beiðni til þjónustu við viðskiptavini okkar og við munum láta þig vita um leið og við getum fengið þau.
Senda beiðni.
Senda beiðni.
Virkt innihaldsefni:
CANDESARTAN CILEXETIL
Fáanlegur frá:
BIOMED PHARMA
ATC númer:
C09CA06
INN (Alþjóðlegt nafn):
CANDESARTAN
Skammtar:
32MG
Lyfjaform:
TABLET
Samsetning:
CANDESARTAN CILEXETIL 32MG
Stjórnsýsluleið:
ORAL
Einingar í pakka:
100
Gerð lyfseðils:
Prescription
Lækningarsvæði:
ANGIOTENSIN II RECEPTOR ANTAGONISTS
Vörulýsing:
Active ingredient group (AIG) number: 0135220004; AHFS:
Leyfisstaða:
CANCELLED PRE MARKET
Leyfisdagur:
2022-07-19
Vara einkenni
_Bio-CANDESARTAN _
_ _
_ _
_ _
_ _
_ _
_ _
_ _
_ _
_ _
_Page 1 of 35 _
_ _
PRODUCT MONOGRAPH
PR
BIO-CANDESARTAN
Candesartan Cilexetil Tablets
4 mg, 8 mg, 16 mg and 32 mg
Angiotensin II AT
1
Receptor Blocker
BIOMED PHARMA
DATE OF PREPARATION:
5950, Côte de Liesse, Suite 100
June 15, 2016
Ville Mont-Royal
Québec H4T 1E2
SUBMISSION CONTROL #: 194909
_Bio-CANDESARTAN _
_ _
_ _
_ _
_ _
_ _
_ _
_ _
_ _
_ _
_Page 2 of 35 _
_ _
TABLE OF CONTENTS
CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
...............................................................................
3
SUMMARY PRODUCT INFORMATION
...............................................................................................
3
INDICATIONS AND CLINICAL USE
.....................................................................................................
3
CONTRAINDICATIONS
..........................................................................................................................
4
WARNINGS AND PRECAUTIONS
.........................................................................................................
4
ADVERSE REACTIONS
...........................................................................................................................
8
DRUG INTERACTIONS
.........................................................................................................................
13
DOSAGE AND ADMINISTRATION
.....................................................................................................
16
OVERDOSAGE
.......................................................................................................................................
19
ACTION AND CLINICAL
PHARMACOLOGY....................................................................................
19
STORAGE AND STABILITY
.................................................................................................................
21
DOSAGE FORMS, COMPOSITION AND PACKAGING
....................................................................
22
Lestu allt skjalið
